Abstract
1 The antihypertensive effect of the combined use of the new calcium channel blocker nicardipine and atenolol was assessed in a double-blind, placebo-controlled trial involving twenty hypertensive patients.
2 Atenolol 100 mg once daily was given to all patients. In addition, either placebo or nicardipine, in increasing doses (5-20 mg three times daily), was allocated randomly to the patients.
3 Compared with placebo, nicardipine had an additional dose-dependent, blood-pressure-lowering effect in the hypertensive patients who had been pretreated with atenolol. An increase in the heart rate was not observed, suggesting that atenolol prevented reflex activation of sympathetic nerve tone caused by the vasodilating properties of nicardipine.
4 The combination of both atenolol and nicardipine was well tolerated by all patients; side effects were minor and did not cause discontinuation of the treatment. No effects on A-V conduction were observed.
5 It is concluded that the combined administration of nicardipine and atenolol is a useful treatment for hypertension that is well accepted by the patients.
Keywords: atenolol, A-V conduction, combination therapy, essential hypertension, nicardipine
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
- Higuchi S., Shiobara Y. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica. 1980 Dec;10(12):889–896. doi: 10.3109/00498258009033822. [DOI] [PubMed] [Google Scholar]
- Jones R. I., Hornung R. S., Sonecha T., Raftery E. B. The effect of a new calcium channel blocker nicardipine on 24-hour ambulatory blood pressure and the pressor response to isometric and dynamic exercise. J Hypertens. 1983 Jun;1(1):85–89. [PubMed] [Google Scholar]
- Lewis G. R., Morley K. D., Lewis B. M., Bones P. J. The treatment of hypertension with verapamil. N Z Med J. 1978 May 24;87(612):351–354. [PubMed] [Google Scholar]
- Lynch P., Dargie H., Krikler S., Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination. Br Med J. 1980 Jul 19;281(6234):184–187. doi: 10.1136/bmj.281.6234.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
- Seki T., Takenaka T. Pharmacological evaluation of YC-93, a new vasodilator, in healthy volunteers. Int J Clin Pharmacol Biopharm. 1977 Jun;15(6):267–274. [PubMed] [Google Scholar]